Sanofi to Acquire Provention Bio for $2.9B
The FDA has granted Orphan Drug status to Ellipses Pharma’s EP0042, an investigational drug for treatment of patients with acute myeloid leukemia.
The drug candidate is being evaluated for patients with resistance to FLT-3 inhibitors. Approximately one-third of patients have FLT-3 mutations, which are associated with higher risk of relapse.
The drug is currently in a phase 1/2 study and the company also plans to study the drug as a potential monotherapy and in combination with other treatments when a phase 2 dose is confirmed.
Ellipses Pharma is an international drug development company, focused exclusively on the advancement of innovative cancer treatments through the clinic. New treatments for cancer are not progressing fast enough. Ellipses is dedicated to making a difference.
Headquartered in London, Ellipses is run by a world class leadership team, overseeing a rapidly growing pipeline of high quality clinical oncology opportunities. Supported by privileged partnerships with leading academic institutions, research bodies, universities, Big Pharma and extensive professional networks, Ellipses Pharma aims to be the most direct route from the research laboratory to patients for cancer treatments.
Clinical trials are the route to developing more cancer treatments. All too often they have become overly complex and expensive, slowing down the progress of new discoveries and new treatments for patients. We streamline the clinical trials process that so often inhibits the progress of new potential drugs with one overarching objective - making more treatments available to patients.
Ellipses provides a permanent source of capital for the development of cancer assets via a scalable business model, and is able to conduct multiple oncology clinical trials in parallel. Supported by our Scientific Affairs Group which comprises many of the world's leading oncologists, Ellipses is taking a new, ambitious approach to significantly impact the cancer drug development market.
Ellipses Pharma has implemented a disruptive approach to cancer drug development that greatly accelerates the delivery of novel solutions for patients. With seven lead products and a growing pipeline of assets, the company is planning to have a first drug ready for out-licensing in 2024.
March 15, 2023
